This is a summary of the European public assessment report (EPAR) for Equioxx.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Equioxx.
For practical information about using Equioxx, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Equioxx : EPAR - Summary for the public (PDF/78.6 KB)
First published: 30/06/2008
Last updated: 06/03/2017
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
|Date of issue of marketing authorisation valid throughout the European Union||
42-46 rue Mederic
12/03/2021 Equioxx - EMEA/V/C/000142 - IB/0025/G
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Anti-inflammatory and anti-rheumatic products, non-steroids
Alleviation of pain and inflammation associated with osteoarthritis and reduction of associated lameness in horses.
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 16-17 February 202119/02/2021